ABCD2 inhibitors belong to a distinct chemical class characterized by their ability to modulate the activity of the ABCD2 protein. These inhibitors are designed to interact with the specific binding sites or active regions of the ABCD2 protein, which plays a crucial role in certain biological processes. The structural framework of ABCD2 inhibitors typically consists of a combination of diverse chemical moieties, allowing for targeted interactions with the protein's functional domains. These inhibitors are designed using computational modeling, structure-activity relationship studies, and medicinal chemistry approaches to ensure their specificity and potency.
The development of ABCD2 inhibitors involves iterative optimization of their chemical structures to enhance their binding affinity and selectivity for the ABCD2 protein. Through intricate modifications, scientists aim to create inhibitors that can effectively hinder the ABCD2 protein's activity by competitively binding to its active sites. The study and synthesis of ABCD2 inhibitors contribute to a deeper understanding of the protein's role in cellular pathways and offer avenues for further research in the field of molecular modulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Inhibits ABCB1 (P-glycoprotein) by binding to it and preventing efflux of substrates, increasing drug levels in cells. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Binds to ABCB1 and modifies its conformation, blocking its efflux function and increasing drug intracellular concentrations. | ||||||
Quinidine | 56-54-2 | sc-212614 | 10 g | $104.00 | 3 | |
Inhibits ABCB1 by competing for its drug-binding sites, effectively blocking the transport of substrates. | ||||||
Elacridar | 143664-11-3 | sc-207613A sc-207613 sc-207613B sc-207613C sc-207613D | 5 mg 10 mg 50 mg 100 mg 1 g | $98.00 $113.00 $411.00 $525.00 $2606.00 | 19 | |
Potent inhibitor of ABCB1, preventing drug efflux and enhancing the intracellular accumulation of substrates. | ||||||
Ko 143 | 461054-93-3 | sc-204030 sc-204030A | 1 mg 10 mg | $109.00 $261.00 | 21 | |
Highly specific inhibitor of ABCG2, blocking its efflux function and increasing the sensitivity of cancer cells to chemotherapy. | ||||||
Fumitremorgin C | 118974-02-0 | sc-202162 | 250 µg | $408.00 | 5 | |
Inhibits ABCG2 by binding to its substrate-binding site, reducing the efflux of anticancer drugs and enhancing their effects. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Acts as an inhibitor of ABCG2, increasing the oral bioavailability and brain penetration of certain chemotherapeutic agents. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Inhibits ABCG2 and other transporters, improving the oral bioavailability of co-administered drugs. | ||||||